Exscientia (EXAI)
| Bid | n/a |
| Market Cap | 633.18M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.51 |
| PE Ratio (ttm) | -3.21 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | n/a |
| Volume | 1,454,597 |
| Avg. Volume (20D) | 704,603 |
| Open | 4.60 |
| Previous Close | 4.84 |
| Day's Range | 4.60 - 4.84 |
| 52-Week Range | 3.80 - 7.91 |
| Beta | undefined |
About EXAI
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to p...
Analyst Forecast
According to 4 analyst ratings, the average rating for EXAI stock is "Hold." The 12-month stock price forecast is $7, which is an increase of 44.63% from the latest price.
4 months ago · businesswire.com
Exscientia Achieves Milestones for Two Programmes in Sanofi CollaborationOXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving a...
6 months ago · businesswire.com
Exscientia Business Update for Second Quarter and First Half 2024OXFORD, U.K.--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the second quarter and firs...
